Functions of microRNA-33a/b and microRNA therapeutics

Journal of Cardiology

Volumn 67, Issue 1, 2016, Pages 28-33

  Ono, Koh ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

ABCA1; Antisense oligonucleotides; HDL C; Plaque

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 33A; MICRORNA 33B; UNCLASSIFIED DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; TRANSCRIPTION REGULATION; VASCULITIS; VIRAL GENE DELIVERY SYSTEM; ANTAGONISTS AND INHIBITORS; METABOLISM; PHYSIOLOGY;

ATHEROSCLEROSIS; CHOLESTEROL, HDL; HUMANS; LIPID METABOLISM; MICRORNAS;

EID: 84955127432     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.10.017     Document Type: Review

References (30)

1. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
2. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
3. Rottiers V., Naar A.M. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012, 13:239-250.
4. Chim S.S., Shing T.K., Hung E.C., Leung T.Y., Lau T.K., Chiu R.W., Lo Y.M. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008, 54:482-490.
5. Kuwabara Y., Ono K., Horie T., Nishi H., Nagao K., Kinoshita M., Watanabe S., Baba O., Kojima Y., Shizuta S., Imai M., Tamura T., Kita T., Kimura T. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 2011, 4:446-454.
6. Moore K.J., Rayner K.J., Suarez Y., Fernandez-Hernando C. microRNAs and cholesterol metabolism. Trends Endocrinol Metab 2010, 21:699-706.
7. Norata G.D., Sala F., Catapano A.L., Fernandez-Hernando C. MicroRNAs and lipoproteins: a connection beyond atherosclerosis?. Atherosclerosis 2013, 227:209-215.
8. Wang L., Jia X.J., Jiang H.J., Du Y., Yang F., Si S.Y., Hong B. MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition. Mol Cell Biol 2013, 33:1956-1964.
9. Horie T., Ono K., Horiguchi M., Nishi H., Nakamura T., Nagao K., Kinoshita M., Kuwabara Y., Marusawa H., Iwanaga Y., Hasegawa K., Yokode M., Kimura T., Kita T. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A 2010, 107:17321-17326.
10. Horie T., Baba O., Kuwabara Y., Chujo Y., Watanabe S., Kinoshita M., Horiguchi M., Nakamura T., Chonabayashi K., Hishizawa M., Hasegawa K., Kume N., Yokode M., Kita T., Kimura T., et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE(-/-) mice. J Am Heart Assoc 2012, 1:e003376.
11. Horie T., Nishino T., Baba O., Kuwabara Y., Nakao T., Nishiga M., Usami S., Izuhara M., Sowa N., Yahagi N., Shimano H., Matsumura S., Inoue K., Marusawa H., Nakamura T., et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun 2013, 4:2883.
12. Horie T., Nishino T., Baba O., Kuwabara Y., Nakao T., Nishiga M., Usami S., Izuhara M., Nakazeki F., Ide Y., Koyama S., Sowa N., Yahagi N., Shimano H., Nakamura T., et al. MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. Sci Rep 2014, 4:5312.
13. Rayner K.J., Suarez Y., Davalos A., Parathath S., Fitzgerald M.L., Tamehiro N., Fisher E.A., Moore K.J., Fernandez-Hernando C. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010, 328:1570-1573.
14. Brown M.S., Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997, 89:331-340.
15. Najafi-Shoushtari S.H., Kristo F., Li Y., Shioda T., Cohen D.E., Gerszten R.E., Naar A.M. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010, 328:1566-1569.
16. Allen R.M., Marquart T.J., Albert C.J., Suchy F.J., Wang D.Q., Ananthanarayanan M., Ford D.A., Baldan A. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med 2012, 4:882-895.
17. Rayner K.J., Sheedy F.J., Esau C.C., Hussain F.N., Temel R.E., Parathath S., van Gils J.M., Rayner A.J., Chang A.N., Suarez Y., Fernandez-Hernando C., Fisher E.A., Moore K.J. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011, 121:2921-2931.
18. Tang C., Liu Y., Kessler P.S., Vaughan A.M., Oram J.F. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem 2009, 284:32336-32343.
19. Goedeke L., Salerno A., Ramirez C.M., Guo L., Allen R.M., Yin X., Langley S.R., Esau C., Wanschel A., Fisher E.A., Suarez Y., Baldan A., Mayr M., Fernandez-Hernando C. Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol Med 2014, 6:1133-1141.
20. Davalos A., Goedeke L., Smibert P., Ramirez C.M., Warrier N.P., Andreo U., Cirera-Salinas D., Rayner K., Suresh U., Pastor-Pareja J.C., Esplugues E., Fisher E.A., Penalva L.O., Moore K.J., Suarez Y., et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011, 108:9232-9237.
21. Herrera-Merchan A., Cerrato C., Luengo G., Dominguez O., Piris M.A., Serrano M., Gonzalez S. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 2010, 9:3277-3285.
22. Rayner K.J., Esau C.C., Hussain F.N., McDaniel A.L., Marshall S.M., van Gils J.M., Ray T.D., Sheedy F.J., Goedeke L., Liu X., Khatsenko O.G., Kaimal V., Lees C.J., Fernandez-Hernando C., Fisher E.A., et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011, 478:404-407.
23. Grunweller A., Hartmann R.K. Locked nucleic acid oligonucleotides: the next generation of antisense agents?. BioDrugs 2007, 21:235-243.
24. Rottiers V., Obad S., Petri A., McGarrah R., Lindholm M.W., Black J.C., Sinha S., Goody R.J., Lawrence M.S., Delemos A.S., Hansen H.F., Whittaker S., Henry S., Brookes R., Najafi-Shoushtari S.H., et al. Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci Transl Med 2013, 5:212ra162.
25. Young J.A., Ting K.K., Li J., Moller T., Dunn L., Lu Y., Moses J., Prado-Lourenco L., Khachigian L.M., Ng M., Gregory P.A., Goodall G.J., Tsykin A., Lichtenstein I., Hahn C.N., et al. Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27. Blood 2013, 122:2911-2919.
26. Winbanks C.E., Beyer C., Hagg A., Qian H., Sepulveda P.V., Gregorevic P. miR-206 represses hypertrophy of myogenic cells but not muscle fibers via inhibition of HDAC4. PLOS ONE 2013, 8:e73589.
27. Montgomery R.L., Yu G., Latimer P.A., Stack C., Robinson K., Dalby C.M., Kaminski N., van Rooij E. MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol Med 2014, 6:1347-1356.
28. Bader A.G. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 2012, 3:120.
29. Kubo T., Yanagihara K., Takei Y., Mihara K., Sato Y., Seyama T. Lipid-conjugated 27-nucleotide double-stranded RNAs with dicer-substrate potency enhance RNAi-mediated gene silencing. Mol Pharm 2012, 9:1374-1383.
30. Chen Y., Zhu X., Zhang X., Liu B., Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010, 18:1650-1656.